The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ji Yun | - |
dc.contributor.author | Oh, Il-Young | - |
dc.contributor.author | Lee, Ju-Hyeon | - |
dc.contributor.author | Kim, Sang-Young | - |
dc.contributor.author | Kwon, Seong Soon | - |
dc.contributor.author | Yang, Hyeon-Jong | - |
dc.contributor.author | Kim, Yang-Ki | - |
dc.contributor.author | Bang, Soo-Mee | - |
dc.date.accessioned | 2021-08-11T08:31:47Z | - |
dc.date.available | 2021-08-11T08:31:47Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 0049-3848 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2368 | - |
dc.description.abstract | Introduction: Direct oral anticoagulants (DOACs) have the potential to increase bleeding due to drug-drug interactions (DDIs). In the present study, the risk of bleeding was evaluated when drugs with potential DDIs were simultaneously prescribed with DOACs. Materials and methods: The present study included patients with non-valvular atrial fibrillation (AF) and venous thromboembolism (VTE) who were newly prescribed DOACs between January 2014 and December 2016. Results: The study included 115,362 patients with AF or VTE who were newly administered DOACs (median age, 73 years, range, 19-108 years; males, 53.0%; AF, 81.9%). A total of 7001 any bleeding (6.1%) and 2283 major bleeding (2.0%) events occurred with DOAC prescriptions. Based on multiple logistic regression analysis, the number of DDIs was significantly associated with bleeding events independent of CHA2DS2-VASc score and Charlson Comorbidity Index (CCI). The rates of exposure to DDI drugs associated with any bleeding and major bleeding were 56.7% and 66.1%, respectively. The most common DDI drugs showed similar distributions in any or major bleeding; non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, diltiazem, and amiodarone were frequently prescribed. Conclusions: Physicians prescribing DOACs for AF or VTE should be aware of the increasing risk of bleeding associated with drugs having potential DDIs regardless of comorbidities. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Pergamon Press | - |
dc.title | The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.thromres.2020.07.054 | - |
dc.identifier.scopusid | 2-s2.0-85089515563 | - |
dc.identifier.wosid | 000583278500046 | - |
dc.identifier.bibliographicCitation | Thrombosis Research, v.195, pp 243 - 249 | - |
dc.citation.title | Thrombosis Research | - |
dc.citation.volume | 195 | - |
dc.citation.startPage | 243 | - |
dc.citation.endPage | 249 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | SEROTONIN REUPTAKE INHIBITORS | - |
dc.subject.keywordPlus | ATRIAL-FIBRILLATION | - |
dc.subject.keywordPlus | NETWORK METAANALYSIS | - |
dc.subject.keywordPlus | PRACTICAL GUIDE | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | AMIODARONE | - |
dc.subject.keywordAuthor | Direct oral anticoagulant | - |
dc.subject.keywordAuthor | Drug-drug interaction | - |
dc.subject.keywordAuthor | Bleeding | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Venous thromboembolism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.